Several other equities research analysts have also recently weighed in on RGLS. Zacks Investment Research cut Regulus Therapeutics from a buy rating to a hold rating in a report on Thursday, January 18th. Leerink Swann assumed coverage on Regulus Therapeutics in a report on Friday, January 5th. They issued an outperform rating and a $2.00 target price for the company. Wedbush reiterated an outperform rating and issued a $4.00 target price on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC restated a hold rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. Regulus Therapeutics currently has an average rating of Hold and an average target price of $2.50.
Shares of Regulus Therapeutics (RGLS) traded down $0.02 during trading on Tuesday, reaching $1.11. The company’s stock had a trading volume of 542,006 shares, compared to its average volume of 613,552. Regulus Therapeutics has a 12 month low of $0.79 and a 12 month high of $1.95. The company has a market cap of $115.39, a P/E ratio of -0.83 and a beta of 1.72. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41.
Institutional investors have recently added to or reduced their stakes in the business. Quantitative Investment Management LLC purchased a new stake in Regulus Therapeutics in the second quarter valued at about $103,000. GSA Capital Partners LLP purchased a new stake in Regulus Therapeutics in the second quarter valued at about $139,000. Royal Bank of Canada increased its holdings in shares of Regulus Therapeutics by 12.1% in the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Regulus Therapeutics by 18.2% in the fourth quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 50,530 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares during the period. Institutional investors own 59.24% of the company’s stock.
WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/02/12/regulus-therapeutics-rgls-neutral-rating-reiterated-at-chardan-capital.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.